HealthDay News – According to a study published in the April 1 issue of the New England Journal of Medicine, treatment with sotatercept results in a decrease in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension.
Marc Humbert, MD, Ph.D., of the Hôpital Bicêtre in Paris, and colleagues conducted the 24-week placebo-controlled phase of a multicenter phase 2 study in which 106 adults who received background therapy for pulmonary arterial hypertension after the Sotatercept randomly treated subcutaneously at a dose of 0.3 or 0.7 mg / kg body weight every three weeks or placebo. There is currently an 18-month extension period for active ingredients for this study.
The researchers found that the mean least squares difference in pulmonary vascular resistance change between the sotatercept 0.3 mg group and the placebo group from baseline through week 24 was -145.8 dynes / s / cm Was -5; The corresponding difference between the sotatercept 0.7 mg group and the placebo group was -239.5 dynes / s / cm -5. At 24 weeks, the mean least squares difference in the six-minute walk distance between the sotatercept 0.3 mg and placebo groups from baseline was 29.4 meters; The corresponding difference between the 0.7 mg sotatercept and placebo groups was 21.4 m. An association for sotatercept with a decrease in natriuretic peptide levels of the N-terminal Pro-B type was also observed. The most common haematological side effects were thrombocytopenia and increased hemoglobin levels.
“Treatment with sotatercept reduced pulmonary vascular resistance in patients with pulmonary arterial hypertension who received stable background therapy, including prostacyclin infusion therapy,” the authors write.
The study was funded by Acceleron Pharma, the maker of Sotatercept.
Summary / full text (subscription or payment required)
Editorial (subscription or payment required)
Subjects:
Hypertension Stroke Treatments
